Overview
An expert faculty of 12 leaders in lung cancer research and clinical care discuss four cases illustrating challenges and recommendations for treating non-small cell lung cancer.

Learning Objectives

• Discuss considerations in assessing patients presenting with advanced NSCLC.
• Discuss considerations in determining first-line treatment options for patients presenting with advanced NSCLC.
• Discuss considerations in integrating supportive care and managing brain metastasis in treatment strategies for patients with advanced NSCLC.
• Implement appropriate treatment and supportive care strategies into practice in assessing, counseling and treating patients with advanced NSCLC.

Program Director
Thomas J. Lynch, Jr., MD
Director, Yale Cancer Center
Physician-in-Chief Smilow Cancer Center at Yale – New Haven
New Haven, Connecticut

Faculty
Tracy T. Batchelor, MD
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Tracey Evans, MD
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Panos Fidias, MD
Massachusetts General Hospital
Center for Thoracic Cancers
Boston, Massachusetts

Glenwood D. Goss, MD, FCPSA, FRCPC
Ottawa Hospital Cancer Centre
Ottawa, Ontario, Canada

Nasser H. Hanna, MD
Indiana University School of Medicine
Indianapolis, Indiana

Daniel D. Karp, MD
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Natasha Leighl, MD, MMSc, FRCPC
Princess Margaret Hospital
Toronto, Ontario, Canada

Lecia V. Sequist, MD, MPH
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Jennifer Temel, MD
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Target Audience
Oncologists and other medical professionals who assess, treat, and counsel patients with lung cancer.

Companion CME Activity
A companion CME activity, Novel Agents in the Treatment of Lung Cancer: New Approaches to First-Line Therapy, based on reviews on recent advances in first-line therapy for non-small cell lung cancer is available at   First-Line Therapies.

Educational Grant Support
Supported by educational grants provided by Bristol-Myers Squibb and ImClone Systems Inc., Boehringer Ingelheim Pharmaceuticals, Inc., and Genentech.

Sponsorship
CME sponsorship and program management provided by InforMEDical Communications.

The CME activity has expired.